Mizuho set a $95.00 price objective on CVS Health (NYSE:CVS) in a report published on Wednesday morning. The brokerage currently has a buy rating on the pharmacy operator’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Robert W. Baird reaffirmed a hold rating and issued a $77.00 price objective on shares of CVS Health in a research note on Friday, October 27th. Needham & Company LLC raised shares of CVS Health from a hold rating to a buy rating and upped their price objective for the company from $69.02 to $79.00 in a research note on Friday, November 10th. Deutsche Bank reaffirmed a hold rating on shares of CVS Health in a research note on Tuesday, December 5th. Raymond James Financial reaffirmed a buy rating on shares of CVS Health in a research note on Monday, December 4th. Finally, Royal Bank of Canada set a $95.00 price objective on shares of CVS Health and gave the company a buy rating in a research note on Monday, December 4th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $87.49.

CVS Health (NYSE CVS) opened at $80.92 on Wednesday. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.00. The company has a market cap of $81,970.00, a P/E ratio of 16.72, a price-to-earnings-growth ratio of 1.26 and a beta of 0.90. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. During the same quarter in the prior year, the company earned $1.64 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. sell-side analysts expect that CVS Health will post 5.88 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.47%. CVS Health’s dividend payout ratio is currently 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.61% of the company’s stock.

A number of large investors have recently bought and sold shares of CVS. Fieldpoint Private Securities LLC raised its holdings in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares in the last quarter. Wealthcare Advisory Partners LLC raised its holdings in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares in the last quarter. Arcadia Investment Management Corp MI raised its holdings in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in CVS Health in the 2nd quarter worth $119,000. Finally, Gemmer Asset Management LLC raised its holdings in CVS Health by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 81.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/01/25/cvs-health-cvs-given-a-95-00-price-target-by-mizuho-analysts.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.